Registry update — unassessed
Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly
Trial registry update: UNKNOWN. No results reported in the supplied registry record.
RCTNotable significance
What this changes
The finding has not established an approved change to our evidence assessment.
Source date: Sep 14, 2016 · Discovered: Sep 15, 2026 · Assessed: — · Historical research backfill
What it does not prove
- The abstract does not state the trial results or outcome data, making it impossible to determine what the study actually found
- Sample size and participant demographics are not reported, limiting assessment of statistical power and generalizability
- The mechanism by which metformin might prevent frailty in non-diabetic individuals is not explained or tested
Extracted from supplied source material; model confidence is not a measured probability of correctness.
Study details
- Design
- Rct
- Sample size
- —
- Duration
- 4 months
- Population
- Pre-frail non-diabetic elderly
- Primary outcome
- Frailty status
- Effect size
- —
- Significance
- Not reported
- Journal
- Indonesia University
- Published
- Sep 14, 2016
Sources
Primary source
- Indonesia University ↗Clinical trial
Recorded source passages
Abstract or registry material supplied for assessment; source version 1. This is not a claim of full-text review.
Title: Randomized-Controlled Trial of Metformin to Prevent Frailty in Pre-frail Elderly
The purpose of this study is to investigate the effects of metformin to prevent frailty in pre-frail non-diabetic elderly. Several outcomes measured in this study are frailty status, quality of life, handgrip strength, gait speed, and serum myostatin levels.
We hypothesize that metformin for 16 weeks could prevent frailty in pre-frail elderly.
Source versions
Assessment history
Discussion (0)
One thread per scientific event, no matter how many outlets covered it.
Sign in to join the discussion.
No comments yet
Be the first to weigh in on this evidence.